Persistent blockade of the pituitary‐gonadal axis in patients with prostatic carcinoma during chronic administration of D‐Trp‐6‐LH‐RH

David Gonzalez‐Barcena, Patricia Perez‐Sanchez, Hector Berea‐Dominguez, Alicia Graef‐Sanchez, Margarita Becerril‐Morales, Ana Maria Comaru‐Schally, Andrew V. Schally

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Forty patients with stage D2 prostatic carcinoma were treated for up to 30 months with D‐Trp‐6‐LH‐RH. The analog was given s.c. once daily at a dose of 1 mg/day for the first 7 days. Subsequently, the dose was reduced to 100 μg/day. In follow‐up studies, 30 men continued this therapy for up to 24 months. Blood samples were taken before the injection of the analog and 1,2,4, and 6 hours later. Serum LH, FSH, and testosterone levels were measured by RIA every month for 2 years. The initial administration of 1 mg D‐Trp‐6‐LH‐RH caused a marked elevation of LH and FSH, which lasted more than 24 hours. However, 1 month later and throughout the therapy, the basal values of LH and FSH were below the normal range and no increase in serum gonadotropins levels was obtained after administration of the analog. Initial plasma testosterone was within normal limits, but during treatment with D‐Trp‐6‐LH‐RH it fell to castration levels, and no increases were seen during the 6 hours following the injection of the analog. These results show that chronic administration of D‐Trp‐6‐LH‐RH, at the doses used, blocks the pituitary‐gonadal axis and that the escape phenomenon from the effects of the LH‐RH agonists‐induced blockade does not occur under our conditions in contrast to observations of Kerle et al with the I.C.I. Analog 118630 (8). The accumulated results reinforce the view that long‐term therapy with agonists of LH‐RH is the preferred alternative to surgical castration or therapy with estrogens in men with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)207-215
Number of pages9
JournalThe Prostate
Issue number2
StatePublished - 1986
Externally publishedYes


  • analogs of LH‐RH
  • human prostate cancer
  • inhibition of LH
  • prostate tumors
  • testosterone

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Persistent blockade of the pituitary‐gonadal axis in patients with prostatic carcinoma during chronic administration of D‐Trp‐6‐LH‐RH'. Together they form a unique fingerprint.

Cite this